Global Immuno-Oncology Drugs Market, by Treatment Type (Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others),  by Disease Type (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others (Breast Cancer, Thyroid Cancer, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  17,394.2 Million in 2022 and is expected to exhibit a CAGR of 16.8% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing adoption of inorganic strategies such as product approval by regulatory authorities such as European Commission (EC) is expected to drive the global immuno-oncology drugs market over the forecast period. For instance, in July 2021, Merck & Co., Inc., a biopharmaceutical company, announced that Keytruda (pembrolizumab) has received the European Commission (EC) approval as monotherapy for the adjuvant treatment in adult patients with renal cell carcinoma (RCC), the most common kidney cancer type. Keytruda is the first immunotherapy to obtain approval in the region for renal cell carcinoma (RCC).

Global Immuno-oncology Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.

Many patients with COVID-19 have severe respiratory infection requires hospitalization and mechanical ventilation and defining the immune responses during COVID-19 could help to identify therapeutics and effective vaccines. However, the COVID-19 pandemic had a negative impact on the global Immuno-oncology drugs market. For instance, in August 2020, according to the data published in National Center for Biotechnology Information, it was estimated that cancer patients are highly vulnerable to COVID-19. Anti-cancer treatments were significantly associated with occurrence of severe clinical events in COVID-19 infections. As cancer treatment is subjected to chemotherapy which is more exposed to infections of COVID-19.

Global Immuno-oncology Drugs Market: Key Developments

Ongoing research and development by key market players is expected to drive the global immuno-oncology drugs market over the forecast period. For instance, in November 2018, Bristol-Myers Squibb Company, a biopharmaceutical company, announced that they had started a clinical trial to study and evaluate the comparison of nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer. This trial is expected to complete in December 2027.

Browse 36 Market Data Tables and 37 Figures spread through 170 Pages and in-depth TOC on “Global Immuno-oncology Drugs Market”- Forecast to 2030, Global Immuno-oncology Drugs Market, by Treatment Type (Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others),  by Disease Type (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others (Breast Cancer, Thyroid Cancer, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/immuno-oncology-drugs-market-1271

For instance, in November 2021, F. Hoffmann-La Roche Ltd., a pharmaceutical company, announced that they had received an approval from European Commission for Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer. Gavreto is the first and only precision medicine approved in the Europe for first-line treatment of people with RET fusion-positive advanced non-small cell lung cancer.

Key Takeaways of the Global Immuno-oncology Drugs Market:

  • The global immuno-oncology drugs market is expected to exhibit a CAGR of 16.8% during the forecast period due to the increasing adoption of inorganic strategies such as research collaboration by the key players over the forecast period. For instance, in April 2020, Gilead Sciences, Inc., a biopharmaceutical company, announced that entered into a three-year cancer immunotherapy research collaboration with ONKO-INNATE, a biotechnology company, to support discovery and development of novel therapies in immuno-oncology and cell therapy.
  • Among disease type, Melanoma is estimated to hold a dominant position in the global immuno-oncology drugs market over the forecast period due to the increasing product approval by regulatory authorities such as U.S. Food and Drug Administration. For instance, in March 2022, Bristol-Myers Squibb Company, a biopharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Opdivo (nivolumab) for the treatment of melanoma.
  • Among regions, North America is estimated to account for the largest market share in the global immuno-oncology drugs market over the forecast period, due to increasing research and development by key market players in that region. For instance, in June 2022, MediMergent, LLC, a biotechnology company, Inc., announced that they started a clinical trial to evaluate the effectiveness of AZD7442 for prevention of COVID-19. This trial is focused on patients with cancer who have been treated with chemotherapy, immunotherapy, targeted therapy, as cancer patients cannot make antibodies against COVID-19.
  • Major players operating in the global Immuno-oncology drugs market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo